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Summary The efficacy of photodynamic therapy (PDT) using 6-aminolaevulinic acid (ALA)-induced
protoporphyrin IX (PpIX) sensitisation and laser light at 635 nm was investigated in the treatment of
experimental hepatic tumours. The model of liver tumours was induced either by local inoculation or by
administration of tumour cells through the portal vein in rats. ALA at a dose of 60 mg kg-' b.w. was
intravenously administered 60 min before PDT. PpIX accumulation in tumour, normal liver and abdominal
wall muscle was detected by means of laser-induced fluorescence (LIF). Laser Doppler imaging (LDI) was used
to determine changes in the superficial blood flow in connection with PDT. Histopathological examinations
were performed to evaluate the PDT effects on the tumour and the surrounding liver tissue, including
pathological features in the microvascular system. The accumulation of PpIX, as monitored by LIF, showed
high fluorescence intensities at about 635 nm in both the hepatic tumour tissue and normal liver and low values
in the abdominal wall. LDI demonstrated that the blood flow in the treated tumour and its surrounding
normal liver tissue decreased immediately after the PDT, indicating an effect on the vascular system. A large
number of thrombi in the irradiated tumour were found microscopically 3 h after the PDT. The tumour growth
rate showed a marked decrease when evaluated 3 and 6 days after the treatment. These results show that the
ALA-PDT is effective in the inhibition of growth of experimental hepatic tumours.
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Malignant tumours of the liver are considered to be highly
therapy-resistant malignancies. Owing to a low resectability,
the 5 year patient survival rate has not exceeded 12-18%
(Adson 1986; Ringe et al., 1991). Although various kinds of
palliative treatment strategies, such as selective embolisation
and ligation of the hepatic artery or the portal branch
(Kawasaki et al., 1994), laser-induced hyperthermia (Hahl et
al., 1990) and cryosurgery (Ravikumar et al., 1991), have
been employed clinically, the prognosis remains unsatisfac-
tory. It has also been shown that chemotherapy and
radiotherapy have a minor impact. Therefore, the develop-
ment of new treatment strategies for this kind of tumour
would be of great importance.
Photodynamic therapy (PDT) is a promising local
treatment modality based on the selective accumulation of a
photosensitiser in malignant tissue and the subsequent
illumination with laser light of an appropriate wavelength.
The laser light excites the molecules of the sensitiser. In an
energy transfer process mediated by the excited sensitiser
molecules, ground-state triplet oxygen in the tissue is excited
to singlet oxygen. Singlet oxygen is known as a highly
cytotoxic agent, causing membrane dysfunction at many
cellular sites. The targets include the membrane of the cell,
nucleus, mitochondrion, lysosome, Golgi apparatus and
endoplasmic reticulum, as well as the endothelium of the
microvascular system (Moan et al., 1982; Henderson et al.,
1985).
During the past years, the role of PDT using intravenously
administered haematoporphyrin derivative (HPD) has been
investigated in the management of experimental hepatic
tumour in rats (Pimestone et al., 1982; Holt et al., 1985;
Nishiwaki et al., 1989). When employing HPD-PDT in liver
tumours it is important to consider that normal liver tissue
accumulates HPD to a very high degree (Gomer and
Dougherty, 1979; Bugelski et al., 1981; Ankerst et al., 1984;
Svanberg et al., 1986). For clinical use the dose-dependent
transient skin sensitisation and the non-optimal light
absorption profile have been considered as other obstacles.
Second-generation photosensitisers, such as benzoporphyrin
(BPD) (Richter et al., 1987) and meso-tetrahydroxyphenyl-
chlorin (Berenbaum et al., 1986), with less pronounced skin
sensitisation (especially for BPD) and more favourable light
absorption profile, have been developed. The distribution of
the substances in various organs and malignant tumour tissue
has been experimentally investigated (Jamieson et al., 1989;
Andersson-Engels et al., 1993; Alian et al., 1994) and clinical
phase I and II trials have been initiated (Ris et al., 1991).
Recently, an alternative method of sensitisation was
introduced by using the haem precursor 3-aminolaevulinic
acid (ALA) (Kennedy et al., 1990; Kennedy and Pottier,
1992). In the metabolic cycle of ALA, owing to variations in
enzyme activity and bypassing of the feedback mechanism, an
accumulation of the photodynamically very active proto-
porphyrin IX (PpIX) occurs in cells after excessive ALA
administration locally, orally or intravenously. In particular,
malignant tumour cells tend to synthesise more PpIX than
non-malignant cells owing to a difference in the content of
the enzymes regulating the haem cycle (Dailey and Smith,
1984; Leibovici et al., 1988). Experimental work and clinical
trials using ALA-induced PpIX sensitisation have been
performed (Malik and Lugaci, 1987; Kennedy et al., 1990;
Kennedy and Pottier, 1992; Bedwell et al., 1992; van
Hillegersberg et al., 1992a,b; Grant et al., 1993; Svanberg et
al., 1994; Warloe et al., 1994).
The aim of the present experimental study was to
investigate the PpIX-mediated PDT effect on rat hepatic
tumours and normal liver following intravenous injection of
ALA. The distribution of PpIX before PDT was monitored
by means of laser-induced fluorescence (LIF). The superficial
blood flow in the tumour and its surrounding normal liver
tissue before and after PDT was studied using a laser
Doppler imaging (LDI) equipment. The histopathological
changes were investigated 3 h, and 3 and 6 days after the
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PDT. The PDT effects were evaluated macroscopically by
calculation of the tumour growth rate 3 and 6 days after the
PDT. Mechanisms involved in this therapeutic modality are
discussed.
Materials and methods
Two models for experimental hepatic tumours with local
inoculation or administration of tumour cells through the
portal vein were used. In total 40 inbred Wistar/Furth rats
weighing 180-200 g were used for tumour induction. The cell
line of the original colon adenocarcinoma was chemically
induced by 1,2-dimethylhydrazine (Hedlund and Sj6gren,
1980). In 30 rats 3 x 105 viable tumour cells were inoculated
into the subcapsular region of the left lateral and the median
lobes of the liver for induction of two primary tumours (Liu
et al., 1993). All 30 rats developed one tumour in each liver
lobe with a mean diameter of 8 +2 mm 8 days after the
inoculation. The tumour in the left lateral lobe was used for
PDT and the other one served as an internal control tumour.
The typical tumour positions in the rat liver are shown in
Figure 1.
In ten rats 1 x 106 viable tumour cells were propagated
into the liver through the portal vein for induction of
secondary hepatic tumours. According to the experimental
data reported by Lafreniere and Rosenberg (1986), 95% of
all metastatic nodules within the parenchyma were found on
the surface of the liver, thus counting only the surface
nodules was thought to be a reliable method ofevaluating the
metastatic depositions. In this group four rats developed
secondary tumours on the surface of the liver 20 days after
the inoculation of tumour cells. The diameter of these
tumours varied between 7 and 10 mm. One of the larger
tumours in each rat liver was employed for PDT.
5-Aminolaevulinic acid hydrochloride (Porphyrin Pro-
ducts, Logan, UT, USA; Lot no. 020592) at a dose of
60 mg kg-' b.w. was dissolved in approximately 2 ml of
isotonic saline, and injected in all animals through the
femoral vein 60 min before the laser irradiation. All rats were
under general anaesthesia induced by chloral hydrate
(250 mg kg-' b.w.) during the procedure.
Figure 1 Schematic view of a rat liver with two inoculated
tumours. Points for LIF measurements are identified in a scan
through the tumour selected for treatment. Recordings from
points E, F, and G are included in the tumour data and from A,
B, C and I, J, K in the normal liver data. The full length of the
scan is about 2-3cm.
Laser-inducedfluorescence
The PpIX fluorescence following laser excitation was
monitored in tumour and liver tissue in 15 rats, and in
abdominal wall muscle in three rats. For the technique of
fluorescence measurements, a fibre optic fluoresensor was
used as described by Andersson-Engels et al. (1991, 1993). As
an excitation source a nitrogen-laser pumped dye-laser was
used, emitting light at 405 nm at a pulse repetition rate of
10 Hz. The full fluorescence spectrum was captured within
the wavelength region 450-750 nm. The intensity of the free-
standing fluorescence emission peak at 635 nm was evaluated,
expressed in terms of an internal fluorescence standard. The
tip of a 600 ,um quartz fibre was put at the surface of the
tumour and its surrounding normal liver tissue. In a scan
across the region, typical measurement points were chosen as
indicated in Figure 1. Fluorescence data were obtained for
each tumour just before the PDT procedure.
Laser Doppler imaging measurements
The superficial blood flow was monitored before and
immediately after the PDT procedure using laser Doppler
imaging equipment (Lisca Development, Linkoping, Sweden).
The light from a 3 mW He-Ne laser is reflected onto the
tissue by an optical mirror system. The light beam (0.8 mm
diameter) scans the object line by line, penetrating the tissue
to a certain depth. In the presence of moving blood cells a
fraction of the back-scattered and Doppler-broadened light is
detected and converted into an electrical signal. The signal is
processed to scale linearly with blood flow and is eventually
used as an estimator of perfusion, i.e. the product of blood
cell velocity and concentration in the sampling volume
(Wardell et al., 1993).
Photodynamic therapy procedure
Photodynamic therapy was performed 60 min after the
injection of ALA, based on kinetic studies presented by
Johansson et al. (1996). As a treatment laser a frequency-
doubled Nd:YAG laser (Multilase 2500, Technomed Inter-
national, Bron/Paris, France) pumping a dye laser (Multilase
Dye 600, Technomed International) was used. The laser light
at 635 nm was delivered in a single treatment with a total
light dose of 100 J cm-2. The light power density was kept
below 110 mW cm-2 in order to avoid local hyperthermia (in
separate measurements it was checked that no significant
temperature rise occurred). A border zone of 4 mm outside
the tumour was included in the treatment field. The laser
light was delivered perpendicularly to the area through an
optical fibre followed by a microscope lens in order to obtain
an even illumination of the whole area, by imaging the
polished fibre end surface onto the treatment field. Without
this arrangement the laser light intensity will be the highest in
the centre with a gradual fall-off in light intensity towards the
borders of the treated area.
Twenty-nine tumour-bearing rats (25 with primary tumour
and four with secondary tumour) were treated with PDT (five
animals died before PDT). For the follow-up examination the
animals were divided into four groups. Groups I-III had
primary local tumours and consisted of eight, ten and seven
rats respectively. Group I was evaluated 3 h, group II 3 days
and group III 6 days after the PDT. Group IV consisted of
four animals with secondary tumours (portal vein tumour
induction), which were evaluated 3 days after the PDT. In
groups I-III the tumour in the left hepatic lobe was used for
the PDT treatment and the other one located in the median
lobe served as an internal control. In group IV one major
tumour in each animal was chosen for the treatment.
Five rats in each of groups I-III were used to study the
PpIX contents in the liver and tumour tissue. The PpIX
signal in the abdominal wall was also measured in three rats
in group III as mentioned before. The superficial blood flow
was monitored in 17 rats in groups II, III and IV. Before the
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PDT, the tumour size was measured with sliding calipers and
the tumour volume was calculated using the formula
(a x b2) x ir/6, (a=maximum tumour diameter, b=minimum
tumour diameter) (Carlsson et al., 1983). The individual
tumour growth rate was calculated by forming the ratio
betwen the tumour volume after and before PDT in groups
II-IV. In groups II and III the tumour growth reduction
factor was expressed as a ratio between the growth rate ofthe
treated and non-treated tumours after and before PDT. A
tumour growth reduction factor of 1 corresponds to natural
growth, while a factor of 0.5 corresponds to only half of the
tumour growth rate compared with the non-treated control
tumour.
tumour tissue. The abdominal wall exhibited a low
fluorescence intensity compared with the two other tissue
types (Figure 3).
Photodynamic effects
Immediately after the PDT procedure the surface of the
whole irradiated field including the border zone outside the
tumour was observed to be dark red and slightly swollen. The
microscopic investigation at 3 h after the PDT (group I)
revealed many fresh thrombi in the irradiated tumour tissue
(Figures 4 and 5a), but no such changes were seen in the non-
Histological examination
The treated and control tumours and livers in groups I-III
and the treated ones in group IV were fixed in 4%
formaldehyde and embedded in paraffin. Sections were
stained with haematoxylin-eosin (HE) and examined under
a microscope. The necrotic depth of the tumour and its
surrounding normal liver was also measured by a pathologist
using a microscope.
Statistical analysis
The mean value of tumour volume and tumour growth
rate +standard deviation (s.d.) was used to estimate
therapeutic efficacy. Wilcoxon's test was used to evaluate
the changes in tumour volume and growth rate at the
different follow-up points. A P-value<0.05 was considered
statistically significant and P<0.01 highly significant.
Results
Fluorescence investigation
PpIX in vivo was monitored just before the PDT procedure.
Three examples of in vivo fluorescence spectra recorded from
tumour tissue, normal liver and abdominal wall for an
injected rat are shown in Figure 2. The drug-specific dual-
peaked fluorescence with the predominant peak at 635 nm is
clearly seen in all three spectra, especially pronounced for the
malignant tumour and liver tissue. The porphyrin signal
exhibited variations within the larger tumours (dia-
meter>8 mm), while the smaller tumours showed a more
even distribution. The liver tissue and abdominal wall showed
almost no variations within the organ. The results of all
fluorescence data from 15 rats (in total about 80 spectra) as
evaluated in terms of an internal reference showed slightly
higher fluorescence intensity in normal liver as compared with
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Figure 3 Diagram of background-free PpIX-related fluorescence
intensity at 635nm expressed in normalised units for experimental
hepatic tumour, normal liver tissue and abdominal wall muscle.
The data are recorded 60min after i.v. injection of ALA
(60mgkg- l b.w.). The standard deviation indicated is high
owing to variations between animals.
50
Wavelength (nm)
Figure 2 In vivo fluorescence spectra recorded from an
experimental hepatic tumour, normal liver tissue and abdominal
wall muscle in a rat injected intravenously with 60mgkg- 1 b.w. of
ALA 60min earlier. The ALA-induced PpIX-related fluorescence
is characterised by a dual-peaked fluorescence with the
predominant emission at 635nm. The background-free intensity
at 635nm was evaluated.
Figure 4 A histopathological section of tumour tissue 3h after
the ALA-PDT. The laser light was delivered with a total light
dose of lOOJcm-2 and a fluence rate below the hyperthermic
threshold (< 110mWcm-2). Several fresh thrombi (arrows) in the
treated tumour can be seen (haematoxylin-eosin staining,
HEx 115).
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Figure 5 (a) A fresh thrombus in the centre of the picture is seen
in an irradiated tumour 3 h after the ALA-PDT (HE x 370). (b) A
control tumour shows viable tumour cells and a vessel without
thrombus (HE x 370).
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irradiated control tumours (Figure 5b). Thrombi within
necrotic tumour were found in all treated groups. No
formation of thrombi in the surrouding irradiated normal
liver was found.
The treated primary hepatic tumours in group II with a
follow-up time of 3 days showed a marked reduction in the
growth rate compared with the non-treated control tumours
(P<0.001) (Figure 6a). The mean value of the ratio was
1.2+0.6 (s.d.) (range 0.6-2.3) for the treated tumours and
3.2+ 1.5 (s.d.) (range 1.7-6.0) for the non-treated ones. The
ratio between the growth rate of the treated and non-treated
tumours, the tumour growth reduction factor, showed a
mean value of 0.42+0.22 (s.d.) (range 0.15-0.8), illustrating
a clear growth inhibition for the tumours treated with the
PDT (Figure 6b). The microscopic investigation revealed
necrosis with a maximum depth of 7 mm in the tumour area
and a depth from 1.5-2 mm in the treated surrounding
normal liver tissue 3 days after the PDT. The PDT-induced
tumour necrosis in the liver tissue showed a clear
demarcation towards the non-necrotic tissue (Figure 7). The
macroscopic examination 3 days after the PDT procedure
demonstrated a gross change in the texture of the tissue
surface with well-demarcated necrosis in the treated area,
including the surrounding liver tissue.
The histological examination in group III (6 days after
PDT) showed an equally extensive necrosis in the surrounding
normal liver tissue as well as a marked degeneration and
necrosis of tumour cells as shown in group II. The tumour
growth rate in group III showed a pronounced decrease in the
treated tumours compared with the non-treated ones with the
mean value of growth rate of 3.0+ 1.1 (s.d.) (range 1.7-4.7)
and 10.3+6.8 (s.d.) (range 3.5-24) respectively (P<0.02)
(Figure 8a). The tumour growth reduction factor showed the
mean value of0.36+0.22 (s.d.) (range 0.12-0.63) (Figure 8b).
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Figure 6 Tumour growth rate for group II with a follow-up time
of 3 days after the ALA-PDT. The individual tumour growth rate
for the treated and non-treated tumour is expressed as the ratio of
tumour volume before and 3 days after PDT (a). The threshold
value at 1 is marked. A ratio below the threshold corresponds to
a tumour volume reduction 3 days after the PDT. A tumour
growth reduction factor, expressed as the ratio between the
growth rate of the treated and non-treated tumour, is calculated
for each individual animal (b). A tumour growth reduction factor
of 1 corresponds to natural growth (no inhibition induced by
PDT), a tumour growth reduction factor of 0.5 corresponds to
only half of the growth rate compared with the non-treated
control tumour.
Tumour regression was also observed in the group of
secondary hepatic tumours (group IV). The histopathological
examination also revealed a marked necrosis in the tumour
and in the treated surrounding normal liver tissue 3 days
after PDT. A clear decrease in the tumour growth reduction
factor was achieved with the average ratio of 0.78 +0.14
(range 0.60-0.89).
After the PDT procedure an immediate decline of the
blood flow was found in the irradiated tumour and tumour
surrounding tissue (Figure 9). The mean perfusion value of
the treated tumours decreased immediately from a relative
value of 52+10 before treatment to 22+8 after treatment.
The mean perfusion value of the treated surrounding normal
liver tissue also decreased from 44+10 before treatment to
16+8 after treatment. The decreased blood flow lasted during
b
n,.^
I I I I
'5
n nPhotodynamic therapy of hepatic tumours in rats
K Svanberg et al
- - ---a. ..
at t
-1 IS T'e' 'tljmSourl|: -U.; _ Conttltumour
-2
*2:20
G*;1 . :. .
Figure 7 Micrograph of a histopathological section of normal
liver tissue 3 days after PDT. A marked boundary (arrows)
between PDT-induced necrosis and non-affected tissue can be
seen. The liver surface is at the top of the figure (HE x 150).
the follow-up periods of 3 and 6 days. Details of LDI results
for more animals than studied here will be presented
separately.
Discussion
In this study PDT effects mediated by ALA-induced PpIX
sensitisation were investigated in the management of
experimental hepatic tumours. The synthesis of PpIX from
the intravenously administered ALA was monitored by
means of LIF. Our results show that 60 min after the ALA
injection, the tumour and the surrounding normal liver tissue
exhibit typical PpIX fluorescence with the dual-peaked
fluorescence at 635 and 700 nm excited at 405 nm. The high
PpIX signal in normal liver is caused by the fact that liver
tissue has the highest capability for haem synthesis outside
the haematopoietic system (Sardesi et al., 1964). Also, the
tumour tissue showed a remarkably high build-up of PpIX,
with the tumour-liver ratio of 0.8: 1 in our data. It should
be noted that the induced tumour in this study is of non-
hepatic origin. The high accumulation of PpIX in tumour
tissue is facilitated by the altered activity of some of the
enzymes regulating the haem cycle. The porphobilinogen
deaminase exhibits an increased and ferrochelatase a
decreased activity in some malignant tissue (Rubino and
Rasetti, 1966; Schoenfeld et al., 1988; Dailey and Smith,
1984; Leibovici et al., 1988). The abdominal wall muscle
showed a much lower PpIX fluorescence intensity with a ratio
of 0.33: 1 for the abdominal wall-liver and 0.42:1 for the
abdominal wall -tumour.
0
C.
0
I.
.0
e
N.
-1 2 3 4 5 6 7
Experimental animal number
Figure 8 Tumour growth rate for group III with a follow-up
evaluation 6 days after PDT. The tumour growth rate for each
individual is expressed as in Figure 6. The tumour growth
reduction factor, calculated as in Figure 6, is also presented.
The fluorescence intensity at 635 nm showed variations
within the tumour, especially pronounced in larger tumours
with a diameter >8 mm. A high level of protoporphyrin was
detected in the peripheral tissue of the large tumour, which
might be related to the specific hypervasculature of hepatic
tumours. The central area in the larger tumours however,
exhibited a much lower fluorescence intensity at 635 nm. This
might be explained by the presence of an anoxic and necrotic
part in the central area of the tumour. The normal liver tissue
did not show any variation in the PpIX fluorescence. This
variation in drug concentration is of central importance in
the planning of PDT. LIF might thus be useful as a predictor
of the PDT outcome, demarcating areas with less sensitiser
and oxygen, two important parameters influencing the
treatment efficacy. As LIF is a non-invasive method it can
easily be employed in the preoperative planning of PDT with
real-time measurements of the sensitiser. In the development
of clinical PDT, it is of great importance in monitoring the
sensitiser in connection with the treatment procedure. This is
especially valuable in introducing new photosensitising agents
for PDT, such as ALA, for which the best method of
administration and the optimum time intervals for treatment
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Figure 9 Doppler blood perfusion images for a rat liver with two induced tumours, as illustrated in Figure 1. (a) High blood
perfusion before the PDT. The line represents a section through the tumour to be treated for which perfusion values are plotted
below. The arrows mark the tumour borders. (b) The same area after PDT of the chosen tumour with corresponding data.
have not yet been established. A further aspect is the
possibility of using LIF for light dose measurements using
the degree of bleaching of the sensitiser (Andersson et al.,
1992).
Henderson (1985) and Star (1986) have suggested that
damage to the tumour vasculature and formation of thrombi
in the irradiated tumour, resulting from early blood flow
stasis in both arterioles and venules, with arteriolar
vasoconstriction and thrombosis of venules and perivascular
interstitial oedema, are important factors. Also, Pass (1991,
1993) suggested blood vessel damage as an important effect
on tumour in the photochemical process. PDT may also
induce the release of clotting factors and vasoactive
intermediates that can increase blood coagulation and alter
vessel tone in the treated tumour tissue (Evrard et al., 1993;
Pass, 1993). Injury of the vessel endothelium and blood cells
caused by PDT is potentially another cause leading to
vascular obliteration and formation of thrombi in the
irradiated area.
The immediate reduction in the blood flow, as measured
by LDI in this study, indicates a PDT effect on tumour
vessels. This is in accordance with early studies and recent
reports on vascular constriction in connection with PDT
(Selman et al., 1984; Kessel, 1984; Van der Veen et al., 1994;
Roberts et al., 1994; Leveckis et al., 1995). A sharply
decreased blood flow was also noticed by a gross
examination immediately after the irradiation, as the treated
area became darker as a result of the treatment. The change
in colour was especially pronounced in the tumour border
area towards normal liver tissue, in which region the highest
fluorescence intensity values were monitored. The surround-
ing normal liver tissue also exhibited the most pronounced
blood flow decrease as measured by means of LDI (Figure 9).
The histological investigation revealed a large number of
fresh thrombi in the treated tumour tissue 3 h after PDT,
indicating an immediate development of the blood shutdown.
These histopathological changes are consistent with the
results from the examination of LDI. The data from our
study support the findings reported by Henderson et al.
(1985) that PDT-induced destruction of tumour vessels is one
of the major causes of secondary tumour cell death.
Furthermore, the results from LDI also showed a decreased
blood flow 3 and 6 days after the PDT treatment, which
further verifies the above theory. The decreased blood flow
following PDT after haematoporphyrin derivative or ALA
systemic administration is in contrast to the increased blood
flow observed after topical administration of ALA (Wang et
al., 1996). This indicates that different mechanisms are in
action for the two administration modalities.
We have demonstrated a simultaneous increase of the
PpIX signal in normal liver tissue and tumour tissue after the
administration of ALA. The PpIX intensities were found to
be modestly higher in the normal liver tissue than in tumour
tissue. One may question whether the same damage develops
in both tissue types treated with PDT. We did find a large
number of thrombi after the PDT in the treated tumour
vessels, including the treated secondary hepatic tumours, but
not in the surrounding normal liver tissue.
Several possible explanations for this observation could be
put forward. Firstly, it is well known that tumour vessels are
tortuous and lack normal tissue structure; thus they are more
susceptible to damage by the PDT treatment than normal
liver tissue. Several investigators have documented the
formation of platelet thrombi on the wall of treated vessels
because PDT treatment can damage the basement membrane
of vessels and endothelial cells (Henderson et al., 1985).
Secondly, coagulating factors, for example, thromboxane, are
released from the treated tissue during PDT. These can
induce tumour vessel constriction and blood aggregation
followed by the formation of thrombi (Bellnier and
Henderson, 1992). Thirdly, it has been reported that the
blood flow in tumour tissue is slower than in normal liver
tissue (Peterson, 1991), which is another reason for thrombi
forming easily in tumour vessels.
Interestingly, the data from the present study indicate
that the depth of necrosis following the PDT in the tumour
tissue and normal liver does not correlate with the PpIX
content. In other words, normal liver tissue showed a
smaller depth of necrosis than did the treated tumour. We
believe that this may be associated with the following
factors. The colour of normal liver tissue is dark red, which
leads to a strong absorption of the light, i.e. only superficial
penetration of the light occurs during the PDT process
resulting in a surface necrosis only. In contrast, the colour
of rat liver tumour tissue is white or pale, leading to a
reduced absorption of the light. The better distal penetra-
tion of the light causes a deeper necrosis in the treated
tumour.xM Photodynamic therapy of hepatic tumours in rats
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